Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL1244352

NCc1ccc(C(=O)Nc2ccc(Nc3cc(-c4cccc5c4oc4ccccc45)ncn3)cc2)cn1.O=C(O)C(F)(F)F

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIP4K2C Q8TBX8 2/20 0.41
PIP4K2A P48426 4/20 0.38
PIP4K2B P78356 4/20 0.38
PIKFYVE Q9Y2I7 1/20 0.38
LOXL2 Q9Y4K0 1/20 0.37
ABL1 P00519 5/20 0.35
BCR P11274 5/20 0.35
MAPT P10636 4/20 0.35
KDM4E B2RXH2 2/20 0.35
MAPK1 P28482 1/20 0.35
MPL P40238 3/20 0.35
NPC1 O15118 2/20 0.35
HPGD P15428 2/20 0.35
RAB9A P51151 2/20 0.35
ALDH1A1 P00352 1/20 0.35
HSD17B10 Q99714 1/20 0.35
PTGDR2 Q9Y5Y4 1/20 0.34
CCNT1 O60563 1/20 0.34
CDK9 P50750 1/20 0.34
EGFR P00533 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1243832 0.95 PIP4K2C (0.44) PIP4K2CPIP4K2APIP4K2BPIKFYVELOXL2
Trifluoroacetic Acid SCHEMBL1244312 0.91 PIP4K2C (0.45) PIP4K2CPIP4K2APIP4K2BPIKFYVELOXL2
Trifluoroacetic Acid SCHEMBL1244801 0.90 PIP4K2C (0.39) PIP4K2CPIP4K2APIP4K2BPIKFYVELOXL2
Trifluoroacetic Acid SCHEMBL1243561 0.88 LOXL2 (0.41) PIP4K2CPIP4K2APIP4K2BPIKFYVELOXL2
Trifluoroacetic Acid SCHEMBL1242002 0.87 PIP4K2C (0.43) PIP4K2CPIP4K2APIP4K2BPIKFYVEABL1
SCHEMBL1242897 0.86 PIP4K2C (0.43) PIP4K2CPIP4K2APIP4K2BPIKFYVEABL1
Trifluoroacetic Acid SCHEMBL1244400 0.86 PIP4K2C (0.37) PIP4K2CPIP4K2APIP4K2BPIKFYVEABL1
Trifluoroacetic Acid SCHEMBL1243874 0.86 PIP4K2C (0.46) PIP4K2CPIP4K2APIP4K2BPIKFYVEABL1
Trifluoroacetic Acid SCHEMBL1243926 0.86 PIP4K2C (0.48) PIP4K2CPIP4K2APIP4K2BPIKFYVEABL1
Trifluoroacetic Acid SCHEMBL1244552 0.86 PTGS1 (0.43) PIP4K2CPIP4K2APIP4K2BPIKFYVEABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7879853-B2 tyrosisne kinase inhibitors such as N-[4-(6-Dibenzofuran-4-yl-pyrimidin-4-ylamino)-phenyl]-4-morpholin-4-yl-benzamide, used as anticasrcinogenic or antoproliferative agents, especially in the treatment of breast cancer BAYER SCHERING PHARMA AG (DE) 2011-02-01 US disclosed
EP-1763526-B1 4,6-DISUBSTITUTED PYRIMIDINES AND THEIR USE AS PROTEIN KINASE INHIBITORS BAYER SCHERING PHARMA AG (DE) 2009-06-24 EP disclosed
US-20070208034-A1 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors ATLANTA PHARMA AG (DE) 2007-09-06 US disclosed
EP-1763526-A1 4,6-DISUBSTITUTED PYRIMIDINES AND THEIR USE AS PROTEIN KINASE INHIBITORS Altana Pharma AG (DE) 2007-03-21 EP disclosed
WO-2006000589-A1 4,6-DISUBSTITUTED PYRIMIDINES AND THEIR USE AS PROTEIN KINASE INHIBITORS ALTANA PHARMA AG (DE) 2006-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070208034-A1 4,6-disubstituted pyrimidines and their use as protein kinase inhibitors CDK2, DCK, DTYMK PIP4K2C 52/4885PIP4K2A 59/4885PIP4K2B 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.